Endo Pharmaceuticals Solutions (IDEV) Inactive
Filed: 3 Mar 09, 12:00am
 Our People Our Business Our Community Our Patients Town Hall Meeting / Sales Meeting (Excerpts) March 3, 2009 Exhibit (a)(5)(w) |
 1 Ensure Operational Excellence • Fully integrate Indevus assets & capabilities while achieving milestones • Continue to execute the seven elements of an effective compliance program • Ensure global operations efficiency & compliance • Flawlessly execute core business and talent management processes |
 2 Advance Critical Organizational Capabilities • Build organization capabilities through Indevus integration, retaining talent in critical areas • Augment talent pipeline through focused development and key hiring • Expand learning & development opportunities • Implement 2008 Voices Survey action plan |
 3 Indevus Integration Update |
 4 A New Endo • Integration teams executing against the establish course • Focusing on “Best Solutions” • Maximize Value On the path to realizing our vision for the future |
 5 Integration Architecture Integration Steering Committee • Nancy Wysenski, Chair • Caroline Manogue • Ivan Gergel • Nancy Bryan • Larry Cunningham • Bobby Sandage • Daniel Carbery • Nancy Santilli • Mark Bradley Commercial Team L. Romaine Finance Team M. Bradley E. Sweeney BD Team V. Seoni Manufacturing & Operations Team S. Cowan Enterprise Wide Teams: Project Management Office Nancy Santilli, Integration Leader, Mark Bradley, Project Manager R&D Team B. Barto B.deJong HR Team C. Nowrey • Compliance- C. Craven • IT- J. Maguire • Communications- C. Perrin • Legal- D. Macpherson • Branding- D. Bingol |
 6 Integration Activities Timeline & Progress Sales Targets Established & Achievement Integration Team Planning and Implementation Post Merger Org. Structure, Leadership Team & Operating Model Established Basic IT Communications Portfolio Prioritization Synergy Opportunities Evaluation & Implementation Post Merger Corporate Objectives Established & Achieved JAN FEB APR MAY JUN JUL AUG SEP OCT NOV DEC MAR |
 7 Tender Offer This communication is neither an offer to purchase nor a solicitation of an offer to sell securities. Endo Pharmaceuticals Holdings Inc. (“Endo”) has filed a tender offer statement on Schedule TO with the Securities and Exchange Commission, and Indevus Pharmaceuticals, Inc. (“Indevus”) has filed a solicitation/recommendation statement with respect to the tender offer. Investors and Indevus shareholders are strongly advised to read the tender offer statement (including the offer to purchase, letter of transmittal and other offer documents) and the related solicitation/recommendation statement because they contain important information. The offer to purchase, the related letter of transmittal and certain other offer documents, as well as the solicitation/recommendation statement, are available at no charge on the Securities and Exchange Commission’s website at www.sec.gov. In addition, copies of these documents and other filings containing information about Indevus and the transaction can be obtained by all Indevus stockholders, without charge, by directing a request to Indevus Pharmaceuticals, Inc., Attention: General Counsel, 33 Hayden Avenue, Lexington, Massachusetts 02421-7966, by telephone at (781) 861-8444 or on Indevus’ website, www.indevus.com. |